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ABSTRACT
Introduction: There is limited information
published on switching erythropoiesis-
stimulating agent (ESA) treatment for anemia
associated with chronic kidney disease (CKD)
from darbepoetin alfa (DA) to methoxy
polyethylene glycol-epoetin beta (PEG-Epo)
outside the protocol of interventional clinical
studies. AFFIRM (Aranesp Efficiency Relative to
Mircera) was a retrospective, multi-site,
observational study designed to estimate the
population mean maintenance dose conversion
ratio [DCR; dose ratio achieving comparable
hemoglobin level (Hb) between two evaluation
periods] in European hemodialysis patients
whose treatment was switched from DA to
PEG-Epo.
Methods: Eligible patients had received
hemodialysis for C12 months and DA for
C7 months. Data were collected from
7 months before until 7 months after
switching treatment. DCR was calculated for
patients with Hb and ESA data available in both
evaluation periods (EP; Months 1 and 2 were
defined as the pre-switch EP, and Months 6 and
7 as the post-switch EP). Red blood cell
transfusions pre- and post-switch were
quantified.
Results: Of 302 patients enrolled, 206 had data
available for DCR analysis. The geometric mean
DCR was 1.17 (95% CI 1.05, 1.29). Regression
analysis indicated a non-linear relationship
between pre- and post-switch ESA doses; DCR
decreased with increasing pre-switch DA dose.
The geometric mean weekly ESA doses were
24.1 lg DA in the pre-switch EP and 28.6 lg
PEG-Epo in the post-switch EP. Mean Hb was
11.5 g/dL in the pre-switch EP and 11.4 g/dL in
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the post-switch EP. There were 16 transfusions
and 34 units transfused in the pre-switch
period, versus 48 transfusions and 95 units
transfused post-switch. Excluding patients
receiving a transfusion within 90 days of or
during either EP, the DCR was 1.21 (95% CI
1.09, 1.35).
Conclusion: In these hemodialysis patients
switched from DA to PEG-Epo the DCR was
1.17 and 1.21 after accounting for the effect of
transfusions. The number of transfusions and
units transfused increased approximately
threefold from the pre-switch to the post-
switch period.
Keywords: Anemia; Chronic kidney disease;
Darbepoetin alfa; Dose conversion;
Erythropoiesis-stimulating agent; Hematology;
Hemodialysis; Medication switching; Pegylated
erythropoietin beta; Retrospective study
INTRODUCTION
Anemia of chronic kidney disease (CKD)
becomes increasingly prevalent and severe as
kidney function declines [1], with over 90% of
patients who require renal replacement therapy
becoming anemic [2]. In CKD, anemia results
primarily from decreased production of
endogenous erythropoietin (EPO) by the
kidney [3]. The introduction of exogenous
erythropoiesis-stimulating agents (ESAs) to
clinical practice has transformed the care of
patients with CKD, by ameliorating anemia,
reducing transfusion requirements, and
improving quality of life [4].
Over the last 25 years, several originator and
biosimilar ESAs have been introduced for the
management of CKD anemia, starting with the
first generation short-acting recombinant
erythropoietin agents (epoetin alfa and beta)
and latterly with two longer-acting molecules,
darbepoetin alfa (DA) and methoxy
polyethylene glycol-epoetin beta (PEG-Epo),
which combine a significantly increased half-
life and lower binding affinity for the EPO
receptor, allowing them to stimulate
erythropoiesis for longer periods and to be
administered less frequently [5, 6]. DA,
launched in 2001 [5, 7], contains 5 N-linked
oligosaccharide chains, rather than the 3
contained in short-acting epoetins, which
confer an approximately threefold longer
serum half-life and mean residence time,
allowing extended inter-dosing intervals [6].
Pharmacokinetic studies have shown that the
mean ± SD terminal half-life of DA is 21 ± 7.5 h
when administered intravenously (IV) [7]. DA
can be administered once a week (QW) or once
every 2 weeks (Q2W) to hemodialysis patients.
Longer-acting PEG-Epo contains a chemical
bond between an amino group present in
epoetin beta and methoxy polyethylene glycol
(PEG) butanoic acid; the addition of PEG is
responsible for an increase in serum half-life of
epoetin beta, and in CKD patients on dialysis
the terminal half-life of PEG-Epo after IV
administration is 134 h [6, 8]. PEG-Epo was
approved in 2009 for administration Q2W or
once a month (QM) to patients on dialysis
[5, 8].
Randomized clinical studies have reported
data on switching from DA to PEG-Epo
(Stabilizing haemoglobin TaRgets in dialysis
following IV C.E.R.A. Treatment for Anaemia
[STRIATA] [8] and comPArator sTudy of C.E.R.A.
and darbepOetin alfa in patieNts Undergoing
dialySis [PATRONUS] [9]); however, there is a
lack of published literature on switching in
patients receiving routine clinical care (i.e.,
outside interventional clinical trials). The aims
of the Aranesp Efficiency Relative to Mircera
(AFFIRM) study were primarily to estimate the
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maintenance dose conversion ratio (DCR) of
PEG-Epo to DA in a population of European
hemodialysis patients switched from DA to
PEG-Epo and with comparable mean
hemoglobin (Hb) in the pre- and post-switch
periods, and secondarily to investigate
parameters of clinical management of anemia
in this group of patients, in real-world clinical
practice.
METHODS
The AFFIRM study was designed as a
retrospective, longitudinal cohort analysis to
estimate the DCR in a population of
hemodialysis patients achieving comparable
Hb after switching from IV DA to IV PEG-Epo
in a real-world setting. The study sample
comprised adult patients (age C18 years) with
CKD who received maintenance hemodialysis
between January 2008 and August 2011 and
whose ESA treatment was switched from IV DA
to IV PEG-Epo. As the study was entirely
retrospective, ESA switching and dose
conversion were performed without reference
to a study protocol and there was no protocol-
driven intervention in the clinical management
of patients. This article does not contain any
studies with human or animal subjects
performed by any of the authors.
Patients were required to fulfill the following
criteria for study entry: switched from
treatment with DA to treatment with PEG-Epo
at least 7 months before study enrollment;
receipt of hemodialysis for at least 12 months
prior to switching; receipt of IV DA for at least
7 months immediately prior to switching;
receipt of at least 1 dose of PEG-Epo after
switching; and provision of informed consent,
according to local requirements. Patients were
excluded if they had participated in any
interventional study within 30 days before the
7-month period preceding the switch or at any
subsequent time up to 7 months after the
switch.
The enrolling dialysis centers were situated
in France, Germany, Spain and the UK, and
each was expected to enroll a minimum of 20
patients into the study. There was neither any
requirement for a center to have been using DA
as their sole long-acting ESA pre-switch, nor for
every DA-treated patient to have been switched
to PEG-Epo. Dialysis centers were expected to
adhere to European Best Practice Guidelines for
iron repletion [9].
Data on clinical and laboratory parameters
relating to CKD management were abstracted
from patient records and entered into an
anonymized study-specific central database by
study center staff. Data quality and completeness
were aided by automatic edit checks built into
the database software. Data were also manually
reviewed prior to final analysis.
The study comprised a 14-month
observation period. Months -7 to -1
constituted the pre-switch period, with switch
defined as the date of first administration of
PEG-Epo, and Months ?1 to ?7 constituted the
post-switch period. In order to compare stable
clinical scenarios for the purposes of DCR
calculation, data evaluation periods (EPs) were
utilized: Months -2 and -1 were defined as the
pre-switch EP and Months ?6 and ?7 were
defined as the post-switch EP.
All patients who fulfilled pre-specified
criteria for completeness of Hb and dosing
data were included in the DCR analysis: i.e.,
those who had received DA or PEG-Epo as the
only ESA in the 1 month prior to and during the
pre- or post-switch EPs, respectively, and who
had dosing information and at least 1 Hb value
in each of the evaluation periods.
Secondary outcomes included Hb
concentrations and ESA use during the study
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period, and the incidence of red blood cell
(RBC) transfusions.
Statistical Methods
The primary outcome (DCR) for each patient
was calculated as the mean weekly dose of PEG-
Epo during the post-switch EP divided by the
mean weekly dose of DA during the pre-switch
EP. Due to the skewed nature of the dosing data,
mean weekly ESA doses were reported using
geometric means; these were derived by
calculating the arithmetic mean of the data
transformed on the natural logarithmic scale.
By definition, the DCR could not be calculated
for patients ineligible for the DCR analysis as
these did not have the necessary parameters
recorded in both EPs.
An additional analysis was performed to
explore the effect of transfusions on the DCR,
by exclusion of patients with a transfusion
within 90 days prior to or during either EP
from the analysis.
The relationship between the DA and PEG-
Epo doses during the evaluation periods was
explored through linear and quadratic
regression. A Bland–Altman analysis [10] was
also performed to assess the agreement between
ESA doses in the evaluation periods.
Hb concentrations were reported as
arithmetic means for each month. RBC
transfusions were reported in terms of number
of transfusions and number of units transfused,
using descriptive statistics. Individual patients
could contribute multiple transfusions to these
analyses. Logistic regression was used to
estimate an odds ratio comparing the number
of patients receiving an RBC transfusion in the
post-switch period relative to their dose ratio at
switch (\1 vs. C1). The distribution of Hb values
reported within the 14 days prior to transfusion
was described; if multiple Hb values were
recorded, the value closest to the transfusion
date was utilized.
The data from this study were analyzed using
SAS Statistical Software v9.2 (SAS Institute Inc.,
Cary, NC, USA).
RESULTS
A total of 302 eligible patients were enrolled at
14 European hemodialysis centers, with 57% of
patients enrolled at 10 French sites, 18% at 2
Spanish sites, 17% at 1 UK site, and 8% at 1
German site. Of the 302 patients enrolled, 206
(68%) were included in the DCR analysis.
Reasons for exclusion of 96 enrolled patients
from the DCR analysis are presented in Fig. 1:
21% of the excluded patients had died or were
lost to follow-up during the post-switch period;
45% were no longer receiving PEG-Epo by
Months ?6 and ?7 post-switch; and 34% had
no Hb value reported for one or both EPs.
The baseline (i.e., at time of switch)
demographic and clinical characteristics of
enrolled patients and those included in and
All enrolled patients:
N = 302
Included in DCR analysis:
n = 206 (68%)
Not included in DCR analysis:
n = 96 (32%)
Reasons for exclusion:a
• Died during post-switch observation 
period: 15 (16%)
• Lost to follow-up during post-switch 
observation period: 5 (5%)
• ESA other than PEG-Epo within 1 
month prior to or during post-switch 
EP: 43 (45%)
• Hb not available for either or both 
EPs: 33 (34%)
Fig. 1 Disposition of patients. aMutually exclusive catego-
ries; patients are censored in the following order: ﬁrst at
death post-switch, then at loss to follow-up post-switch,
then at receipt of an ESA other than PEG-Epo, and ﬁnally
lack of an Hb measurement in either or both EPs. DCR
geometric mean maintenance dose conversion ratio, EP
evaluation period, ESA erythropoiesis-stimulating agent,
Hb hemoglobin, PEG-Epo methoxy polyethylene glycol-
epoetin beta
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excluded from the DCR analysis are displayed in
Table 1.
The primary outcome measure, the
geometric mean maintenance DCR, was
calculated to be 1.17 (95% CI 1.05, 1.29). In
an additional analysis performed to assess the
sensitivity of this result to the effects of
transfusion by excluding those patients who
received an RBC transfusion within 90 days
prior to or during either evaluation period, the
DCR was 1.21 (95% CI 1.09, 1.35).
The regression analysis that examined the
relationship between mean weekly ESA doses in
the two evaluation periods indicated that the DCR







N 302 206 96
Patient demographics
Age (years), mean (SD) 65 (15) 62 (15) 65 (15.5)
Gender, male, n (%) 184 (61) 127 (62) 57 (59)
Clinical characteristics
Prior history, n (%)
Diabetes 105 (35) 67 (32) 38 (40)
Cardiovascular disease 199 (66) 139 (67) 60 (62)
Primary etiology of kidney disease, n (%)
Diabetes 70 (23) 44 (21) 26 (27)
Glomerular nephropathy 44 (15) 38 (18) 6 (6)
Hypertension 39 (13) 28 (14) 11 (12)
Interstitial nephropathy 30 (10) 18 (9) 12 (13)
Polycystic kidney disease 14 (5) 12 (6) 2 (2)
Other/unknown 105 (34) 66 (32) 39 (40)
Duration of dialysis (months), median (Q1, Q3) 42 (24, 73) 42 (25, 72) 42 (23, 78)
Darbepoetin alfa dose frequency, n (%)
QW 192 (64) 122 (60) 70 (73)
Q2W 67 (22) 44 (21) 23 (24)
[Q2W 43 (14) 40 (19) 3 (3)
Duration of darbepoetin alfa treatment
(months), median (Q1, Q3)
28 (16, 39) 25 (15, 37) 31 (22, 49)
Mean weekly darbepoetin alfa dose (lg),
geometric mean (95% CI)
27.7 (25.1, 30.5) 24.1 (21.3, 27.1) 37.7 (32.5, 43.6)
Hb (g/dL), mean (SD) 11.5 (1.1) 11.5 (1.1) 11.6 (1.3)
CI conﬁdence interval, DCR dose conversion ratio, Hb hemoglobin, Q1, Q3 interquartile range, Q2W every 2 weeks, QW
once weekly
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is not linear; a significant (P = 0.008) quadratic
term was observed in the regression analysis,
indicating that the predicted DCR decreased at
higher pre-switch doses of DA (Fig. 2).
Results of the Bland–Altman analysis
investigating the concordance between mean
weekly ESA doses in both evaluation periods are
presented in Fig. 3. This analysis indicated that
the concordance decreased with increasing dose.
The geometric mean weekly ESA dose for
those included in the DCR analysis is shown in
Fig. 4. The geometric mean weekly dose of DA
was 23.2 lg (95% CI 20.6, 26.3) in the month
prior to switch. Geometric mean weekly PEG-
Epo dose at Month 1 post-switch was 26.7 lg
(95% CI 24.4, 29.3), rising to 29 lg (95% CI
26.2, 32.2) by Month 7 post-switch. In the
evaluation periods, the geometric mean weekly
DA dose in the pre-switch EP was 24.1 lg (95%
CI 21.3, 27.1) while the geometric mean weekly
PEG-Epo dose in the post-switch EP was 28.6 lg
(95% CI 26.0, 31.5).
Figure 4 also displays the mean monthly Hb
for those included in the DCR analysis over the
study period. The mean (95% CI) monthly Hb
immediately prior to switch, in Month 1 post-
switch, and in Month 7 post-switch was 11.5 g/
dL (11.3, 11.7), 11.7 g/dL (11.5, 11.9), and
11.4 g/dL (11.3, 11.6), respectively.
As shown in Tables 2 and 3, the mean
(standard error) monthly Hb remained stable
Fig. 2 Analysis of relationship between pre- and post-
switch erythropoiesis-stimulating agent dose. 1:1 reference
line indicates equal PEG-Epo and darbepoetin alfa doses.
EP evaluation period, PEG-Epo methoxy polyethylene
glycol-epoetin beta
Fig. 3 Bland–Altman analysis of agreement between pre- and post-switch erythropoiesis-stimulating agent dose (n = 205).
PEG-Epo methoxy polyethylene glycol-epoetin beta
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across the observation period, with mean
monthly concentration ranging from 11.42
(0.09) g/dL (Month -4) to 11.60 (0.09) g/dL
(Month -2) pre-switch, and from 11.26 (0.10)
g/dL (Month 4) to 11.67 (0.09) g/dL (Month 1)
post-switch.
Tables 2 and 3 also summarize the
proportion of patients in different Hb
categories by study month. In the month
immediately prior to switch, the proportions
of patients who had Hb below 10, 10–12, and
above 12 g/dL were 7.3%, 54.4%, and 25.7%,
respectively, with 12.6% missing. In the first
month after switch, these proportions were
10.2%, 48.5% and 37.4%, respectively. By
Month 7 post-switch, the proportions of
patients with Hb in these ranges were 9.7%,
48.1%, and 30.1%, respectively.
Concerning RBC transfusions, 36 patients
received a transfusion; 7 were transfused in the
pre-switch period only, 4 received a transfusion
both pre- and post-switch, and 25 had a
transfusion in the post-switch period only.
There were 16 transfusion events in the pre-
switch period and 48 post-switch, with a total of
34 units transfused pre-switch and 95 units in
Fig. 4 Hemoglobin level and weekly equivalent erythropoiesis-stimulating agent dose during the 14-month observation
period. Values are means (arithmetic for hemoglobin, geometric for dose) with 95% conﬁdence intervals. ESA
erythropoiesis-stimulating agent, Hb hemoglobin
Table 2 Hemoglobin concentration by study month for patients with a measurable DCR (N = 206) during the pre-switch
observation period
Hb category, n (%) Month 27 Month 26 Month 25 Month 24 Month 23 Month 22 Month 21
Mean 11.57 11.52 11.54 11.42 11.52 11.60 11.48
SE 0.09 0.09 0.08 0.09 0.09 0.09 0.08
Broad categories
\10 g/dL 16 (7.8) 16 (7.8) 14 (6.8) 23 (11.2) 21 (10.2) 19 (9.2) 15 (7.3)
C10 to B12 g/dL 91 (44.2) 97 (47.1) 116 (56.3) 106 (51.5) 95 (46.1) 100 (48.5) 112 (54.4)
[12 g/dL 61 (29.6) 66 (32.0) 66 (32.0) 56 (27.2) 65 (31.6) 65 (31.6) 53 (25.7)
Missing 38 (18.4) 27 (13.1) 10 (4.9) 21 (10.2) 25 (12.1) 22 (10.7) 26 (12.6)
When multiple assessments were available for a patient, the single assessment closest to center of the interval was used.
DCR geometric mean maintenance dose conversion ratio, Hb hemoglobin
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the post-switch period (Fig. 5). Logistic
regression analysis showed a higher likelihood
of a transfusion during the post-switch period
among patients with a dose ratio at switching of
\1. Of the 29 patients transfused during the
post-switch period, 20 had a dose ratio at switch
\1, and 9 had a dose ratio at switch C1 (odds
ratio 2.39, 95% CI 1.05, 5.44; P = 0.038). The
pre-transfusion Hb concentrations were similar
for transfusions occurring both pre- and post-
switch (Fig. 6); the mean (SD) Hb within 14 days
prior to transfusion in these periods was 8.8
(1.41) and 8.3 (1.26), respectively. The majority
of patients who were transfused during the pre-
and post-switch observation periods had Hb
B10 g/dL within the 14 days prior to
transfusion; only 1 patient during each period
had Hb [11 g/dL within the 14-day pre-
transfusion interval.
DISCUSSION
This paper presents the findings of a
retrospective, multi-center, observational study
of hemodialysis patients switched from DA to
PEG-Epo for the treatment of anemia. The
primary finding of the study is that the DCR
of PEG-Epo to DA was 1.17 (95% CI 1.05, 1.29).
Table 3 Hemoglobin concentration by study month in the DCR subgroup (N = 206) during the post-switch observation
period
Hb category, n (%) Month 1 Month 2 Month 3 Month 4 Month 5 Month 6 Month 7
Mean 11.67 11.43 11.32 11.26 11.31 11.36 11.44
SE 0.09 0.09 0.09 0.10 0.10 0.10 0.09
Broad categories
\10 g/dL 21 (10.2) 29 (14.1) 29 (14.1) 32 (15.5) 28 (13.6) 20 (9.7) 20 (9.7)
C10 to B12 g/dL 100 (48.5) 103 (50.0) 106 (51.5) 111 (53.9) 109 (52.9) 102 (49.5) 99 (48.1)
[12 g/dL 77 (37.4) 64 (31.1) 55 (26.7) 54 (26.2) 54 (26.2) 53 (25.7) 62 (30.1)
Missing 8 (3.9) 10 (4.9) 16 (7.8) 9 (4.4) 15 (7.3) 31 (15.0) 25 (12.1)
When multiple assessments were available for a patient, the single assessment closest to center of the interval was used.
DCR geometric mean maintenance dose conversion ratio, Hb hemoglobin
Fig. 5 Red blood cell transfusions pre- and post-switch
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Accounting for the effect of transfusion, the
DCR was 1.21 (95% CI 1.09, 1.35).
The PATRONUS study, in which stable
hemodialysis patients receiving IV DA were
randomized either to QM PEG-Epo or to Q2W
DA for 26 weeks [11], described an increase in
post-switch dose requirement. Among patients
switched from DA to PEG-Epo, the mean
monthly PEG-Epo dose was increased from
159 lg at the switch to 263 lg at Week 26 and
273 lg at Month 11–12 [11]. In contrast, in the
STRIATA study where stable hemodialysis
patients receiving IV DA were randomized to
Q2W PEG-Epo (outside current label guidance)
or to continue on DA QW or Q2W, median
PEG-Epo doses were described as stable across
the 52-week post-switch period, although mean
dose data were not reported [12].
AFFIRM demonstrated non-linearity of the
dose relationship curve, with DCR decreasing as
pre-switch DA dose increased. Further
exploration of the relationship between DA
and PEG-Epo doses using the Bland–Altman
method [10], which circumvents the limitations
of the regression method in this type of
investigation, indicated that the variability in
the dose differences increased as doses
increased, while the level of concordance
decreased with increasing ESA dose. This was
particularly evident in patients whose pre-
switch EP weekly DA dose was higher than
100 lg.
Excursions of Hb values above and below the
range of 10–12 g/dL [9] were more common in
the post-switch compared to the pre-switch
period. Fewer than half of the patients
achieved Hb in the 10–12 g/dL range by
7 months post-switch.
The number of RBC transfusions and units
transfused in the post-switch period was
approximately threefold higher compared to
the pre-switch period. In particular, the
likelihood of a transfusion during the post-
switch period was significantly higher in
patients with a dose ratio below 1 at switch.
The odds ratio for receiving a transfusion was
twice as high in patients switched at a dose ratio
less than 1 when compared to those switched at
1:1 or higher. The distribution of transfusions
(Fig. 5) shows that most transfusions occurred
in the first 4 months post-switch. Although the
reasons for transfusion were not recorded, the
Fig. 6 Summary of the last hemoglobin concentrations recorded within 14 days prior to red blood cell transfusions pre- and
post-switch. Asterisk Not all transfusions had an associated hemoglobin concentration in the 14-day period before
transfusion. Hb hemoglobin
Adv Ther (2013) 30:1007–1017 1015
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pre-transfusion Hb concentrations within
14 days prior to transfusion remained similar
for transfusions occurring both pre- and post-
switch. This suggests that the decision to
transfuse was consistent with respect to Hb
over the observation period (Fig. 6). Reasons for
low Hb, e.g., acute intercurrent events such as
bleeding, were not reported. There are
significant negative consequences associated
with increased transfusion requirement in
dialysis patients, including production of
sensitizing anti-human leukocyte antigen
(HLA) antibodies which, despite advances in
immunosuppressant therapy [13], may impair
or prevent transplantation in patients otherwise
eligible for receipt of a kidney graft.
Changes in ESA dosing and number of
transfusions post-switch may have important
health-economic implications. However,
healthcare-resource utilization and cost data
were not collected in this study, preventing
comparison of these variables between the pre-
switch and post-switch periods.
There are limitations in generalizing the
findings of this study to the broader
hemodialysis population. Firstly, the study
sample was drawn largely from a single
country (France), which contributed over 70%
of the patients and 10 of the 14 study sites. The
remaining enrolment was at four sites divided
between three other countries. Secondly, the
DCR was calculated on a subset of patients
which constituted approximately two-thirds of
the total enrolled. Patients included in the
analysis were less likely to be diabetic (32% vs.
40%), more likely to be receiving DA at a longer
dosing interval (60% vs. 73% at QW; 19% vs.
3% less frequently than Q2W), and received a
lower geometric mean weekly dose of DA
during the pre-switch EP (24.1 vs. 37.7 lg). No
test of statistical significance was performed on
any of the clinical characteristics. Regardless of
possible differences in their clinical
characteristics it should be borne in mind that
patients were not selected for inclusion in the
DCR analysis on the basis of their fulfilling any
clinical, Hb or ESA dose requirements: all
patients who had Hb measurements in both
EPs, a DA dose in the pre-switch EP and a PEG-
Epo dose in the post-switch EP were eligible for
inclusion.
CONCLUSION
In conclusion, this study has shown that in a
cohort of European hemodialysis patients who
converted from DA to PEG-Epo (and who
completed 6–7 months’ treatment with PEG-
Epo post-conversion), there was an
approximately 20% increase in the lg dose
required to achieve a comparable Hb profile.
The geometric mean DCR of PEG-Epo to DA
was 1.17, rising to 1.21 when the effect of RBC
transfusions was taken into account. However,
the relationship between the pre- and post-switch
ESA doses during the two evaluation periods was
non-linear. AFFIRM may therefore help to guide
expectations around potential differences in ESA
dose requirements when switching hemodialysis
patients from DA to PEG-Epo, although the
reported mean maintenance DCR is not
intended to predict the dose conversion ratio at
the individual patient level.
Finally, our study indicates that the risk of
transfusion was higher in the post-switch
compared with the pre-switch period, with an
approximate threefold riseobserved in thenumber
of transfusions and units transfused post-switch.
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